Strides Pharma Science is going to receive $42 million towards full and final release of the General Claims Escrow immediately. The company and its wholly owned subsidiary, Strides Pharma Asia Pte completed the sale to Mylan Laboratories and Mylan Institutional Inc of Agila Specialties and Agila Specialties Global Pte respectively, pursuant to Sale and Purchase Agreements effective as of February 27, 2013 (SPAs) on December 04, 2013.
Mylan made claims against the General Claims Escrow which included a third-party claim that was subject to resolution under international arbitration. The claims in that arbitration were rejected in their entirety. Hence, Strides will receive around $42 million towards full and final release of the General Claims Escrow immediately.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1831.30 |
| Dr. Reddys Lab | 1307.00 |
| Cipla | 1361.00 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2460.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: